{"organizations": [], "uuid": "97785e561b7c508356e117565161f69ee0cfe72c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180410.html", "section_title": "Archive News &amp; Video for Tuesday, 10 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-luye-pharma-group-says-ly03003-dru/brief-luye-pharma-group-says-ly03003-drug-approved-to-proceed-to-phase-iii-clinical-trials-in-china-idUSFWN1RM0U8", "country": "US", "domain_rank": 408, "title": "BRIEF-Luye Pharma Group Says LY03003 Drug Approved To Proceed To Phase III Clinical Trials In China", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.96, "site_type": "news", "published": "2018-04-10T13:42:00.000+03:00", "replies_count": 0, "uuid": "97785e561b7c508356e117565161f69ee0cfe72c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-luye-pharma-group-says-ly03003-dru/brief-luye-pharma-group-says-ly03003-drug-approved-to-proceed-to-phase-iii-clinical-trials-in-china-idUSFWN1RM0U8", "ord_in_thread": 0, "title": "BRIEF-Luye Pharma Group Says LY03003 Drug Approved To Proceed To Phase III Clinical Trials In China", "locations": [], "entities": {"persons": [], "locations": [{"name": "china", "sentiment": "none"}, {"name": "china", "sentiment": "none"}], "organizations": [{"name": "brief-luye pharma group", "sentiment": "negative"}, {"name": "reuters) - luye pharma group ltd", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 10 (Reuters) - Luye Pharma Group Ltd:\n* LY03003 OBTAINED APPROVAL FROM CHINA FOOD AND DRUG ADMINISTRATION TO PROCEED TO PHASE III CLINICAL TRIALS IN CHINA Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-10T13:42:00.000+03:00", "crawled": "2018-04-11T17:59:07.053+03:00", "highlightTitle": ""}